About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Bempedoic Acid
- Company
- Taipei Medical University Hospital
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 11 recruiting
Efficacy results: Not yet reported
11 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 18, 2026
Find a Clinical Trial Near Me
See recruiting studies for Bempedoic Acid and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT05103254
Bempedoic Acid Pregnancy Surveillance Program
Esperion Therapeutics, Inc. 20 participants Est. completion 2032-05 1 siteOther conditions: Pregnancy, HyperlipidemiasView official trial listing → -
Recruiting NCT NCT05488431
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
Not yet reported Priscilla Hsue, MD 121 participants Est. completion 2028-03-01 3 sites Stand-aloneCardiovascular disease Other conditions: Dyslipidemias, HIV Infections, AtherosclerosisView official trial listing → -
Recruiting NCT NCT06035874
Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Not yet reported Medanta, The Medicity, India 100 participants Est. completion 2025-10-01 1 siteType 2 diabetes Other conditions: Non Alcholic Fatty Liver DiseaseView official trial listing → -
Recruiting NCT NCT06501443
LATAM LOWERS LDL-C
Not yet reported Novartis Pharmaceuticals 520 participants Est. completion 2026-11-29 11 sitesOther conditions: HypercholesterolaemiaView official trial listing → -
Recruiting NCT NCT06686615
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 2000 participants Est. completion 2028-01-31 163 sitesOther conditions: Primary Hypercholesterolemiia, Mixed DyslipidemiaView official trial listing → -
Recruiting NCT NCT06780410
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
Not yet reported Gan & Lee Pharmaceuticals. 240 participants Est. completion 2025-10 1 site Stand-aloneOther conditions: Primary HyperlipidemiaView official trial listing → -
Recruiting NCT NCT07206472
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Daiichi Sankyo 2120 participants Est. completion 2028-12-31 23 sitesOther conditions: Primary Hypercholesterolaemia, Mixed DyslipidemiaView official trial listing → -
Recruiting NCT NCT07374861
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy
Federico II University 1500 participants Est. completion 2028-12-31 1 siteOther conditions: HypercholesterolemiaView official trial listing → -
Recruiting NCT NCT07611747
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
Not yet reported Instituto de Investigación Marqués de Valdecilla 1944 participants Est. completion 2031-12 17 sites Stand-aloneOther conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondy, Systemic Lupus Erythematosus (SLE), Caridovascular Disease, Atherosclerosis, Carotid Artery DiseasesView official trial listing → -
Recruiting NCT NCT07614958
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Not yet reported A. Menarini International Licensing S.A. 426 participants Est. completion 2027-01 1 site Stand-aloneOther conditions: Mixed Dyslipidemia, HypercholesterolaemiaView official trial listing → -
Recruiting NCT NCT07824323
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
Not yet reported Taipei Medical University Hospital 400 participants Est. completion 2028-12 1 site Stand-aloneOther conditions: Acute Coronary Syndromes, DyslipidemiaView official trial listing → -
Completed NCT NCT02659397
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
Not yet reported Esperion Therapeutics, Inc. 68 participants Est. completion 2016-07 19 sitesOther conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT02666664
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
Not yet reported Esperion Therapeutics, Inc. 2230 participants Est. completion 2018-03-28 104 sitesCardiovascular disease Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT02988115
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Not yet reported Esperion Therapeutics, Inc. 345 participants Est. completion 2018-03-16 67 sites Stand-aloneCardiovascular disease Other conditions: Hypercholesterolemia, Statin Adverse ReactionView official trial listing → -
Completed NCT NCT02991118
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Not yet reported Esperion Therapeutics, Inc. 779 participants Est. completion 2018-08-22 2 sites Stand-aloneCardiovascular disease Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT02993406
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
Not yet reported Esperion Therapeutics, Inc. 13970 participants Est. completion 2022-11-07 1319 sites Stand-aloneCardiovascular disease Other conditions: Statin Adverse ReactionView official trial listing → -
Completed NCT NCT03001076
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
Not yet reported Esperion Therapeutics, Inc. 269 participants Est. completion 2018-02-12 1 site Stand-aloneOther conditions: Hypercholesterolemia, Atherosclerosis, Statin Adverse ReactionView official trial listing → -
Completed NCT NCT03051100
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Not yet reported Esperion Therapeutics, Inc. 63 participants Est. completion 2017-07-05 11 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT03067441
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
Not yet reported Esperion Therapeutics, Inc. 1462 participants Est. completion 2019-11-05 3 sites Stand-aloneCardiovascular disease Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT03193047
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
Not yet reported Esperion Therapeutics, Inc. 59 participants Est. completion 2018-02-19 1 site Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT03337308
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
Not yet reported Esperion Therapeutics, Inc. 382 participants Est. completion 2018-07-18 5 sites Stand-aloneOther conditions: HyperlipidemiasView official trial listing → -
Completed NCT NCT03531905
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
Not yet reported Esperion Therapeutics, Inc. 242 participants Est. completion 2019-06-18 4 sites Stand-aloneType 2 diabetes Other conditions: Diabetes, CholesterolemiaView official trial listing → -
Active, not recruiting NCT NCT04579367
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 5000 participants Est. completion 2026-10-30 443 sitesOther conditions: Hypercholesterolemia, Mixed DyslipidemiaView official trial listing → -
Completed NCT NCT04784442
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Not yet reported Otsuka Pharmaceutical Co., Ltd. 188 participants Est. completion 2022-05-17 1 site Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Status unknown NCT NCT05263778
Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
Not yet reported Kaiser Permanente 500 participants Est. completion 2023-12 1 siteCardiovascular disease Other conditions: NSTEMI, STEMIView official trial listing → -
Completed NCT NCT05543122
Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants
The Hospital for Sick Children 39 participants Est. completion 2024-03-31 1 siteOther conditions: Breast FeedingView official trial listing → -
Completed NCT NCT05546398
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 500 participants Est. completion 2022-11-17 63 sitesOther conditions: Hypercholesterolemia, Mixed DyslipidemiaView official trial listing → -
Not yet recruiting NCT NCT05587621
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
Not yet reported Jena University Hospital 300 participants Est. completion 2026-12-31 10 sitesCardiovascular disease Other conditions: LDL-cholesterolView official trial listing → -
Completed NCT NCT05683340
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Not yet reported Otsuka Pharmaceutical Co., Ltd. 96 participants Est. completion 2024-03-12 1 site Stand-aloneOther conditions: Hyper-low-density Lipoprotein (LDL) CholesterolemiaView official trial listing → -
Completed NCT NCT05687071
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Not yet reported Otsuka Pharmaceutical Co., Ltd. 130 participants Est. completion 2024-11-02 1 site Stand-aloneOther conditions: Hyper-low-density Lipoprotein (LDL) CholesterolemiaView official trial listing → -
Completed NCT NCT05694260
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Not yet reported Esperion Therapeutics, Inc. 31 participants Est. completion 2025-06-04 24 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Withdrawn NCT NCT05798390
Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Est. completion 2026-04-01Other conditions: Primary Hypercholesterolemia, Mixed DyslipidemiaView official trial listing → -
Completed NCT NCT06021951
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
Not yet reported Esperion Therapeutics, Inc. 16 participants Est. completion 2024-03-22 1 site Stand-aloneOther conditions: Healthy Lactating WomenView official trial listing → -
Withdrawn NCT NCT06280976
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
Not yet reported University of Louisville Est. completion 2025-01-01 1 site Stand-aloneCardiovascular disease Other conditions: Atherosclerosis, Heart AttackView official trial listing → -
Status unknown NCT NCT06381947
Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
Not yet reported University of Salerno 130 participants Est. completion 2025-06-30 Stand-aloneCardiovascular disease Other conditions: Dyslipidemias, Statin Adverse Reaction, Lipid Metabolism DisordersView official trial listing → -
Completed NCT NCT06431763
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
Not yet reported Novartis Pharmaceuticals 402 participants Est. completion 2026-01-02 55 sitesOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT06450366
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Not yet reported Merck Sharp & Dohme LLC 301 participants Est. completion 2025-03-28 35 sites Stand-aloneOther conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT06647238
Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention
Not yet reported Wake Forest University Health Sciences 80 participants Est. completion 2025-05-27 1 site Stand-aloneCardiovascular disease Other conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT06742853
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
Not yet reported AstraZeneca 81 participants Est. completion 2025-10-29 3 sites Stand-aloneOther conditions: DyslipidemiaView official trial listing → -
Completed NCT NCT06923956
Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Not yet reported Humanis Saglık Anonim Sirketi 14 participants Est. completion 2025-02-08 1 site Stand-aloneCardiovascular disease Other conditions: Hypercholesterolaemia, Mixed DyslipidaemiaView official trial listing → -
Completed NCT NCT06925100
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
Not yet reported Daiichi Sankyo 180 participants Est. completion 2025-10-15 3 sites Stand-aloneOther conditions: Primary Hypercholesterolemia or Mixed HyperlipidemiaView official trial listing → -
Not yet recruiting NCT NCT07129850
Bempedoic Acid in PPCI Impact on Clinical Outcome and Inflammatory Markers
Assiut University 100 participants Est. completion 2027-11-14Cardiovascular diseaseView official trial listing → -
Completed NCT NCT07170852
Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets
Not yet reported Humanis Saglık Anonim Sirketi 32 participants Est. completion 2025-08-21 1 site Stand-aloneOther conditions: HypercholesterolaemiaView official trial listing → -
Completed NCT NCT07182383
Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin
Not yet reported Daiichi Sankyo 58 participants Est. completion 2025-11-24 1 site Stand-aloneOther conditions: Healthy SubjectsView official trial listing → -
Completed NCT NCT07201545
Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin
Not yet reported Daiichi Sankyo 58 participants Est. completion 2025-12-10 1 site Stand-aloneOther conditions: Healthy SubjectsView official trial listing → -
Completed NCT NCT07235189
A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin
Not yet reported Daiichi Sankyo 58 participants Est. completion 2026-01-28 1 site Stand-aloneOther conditions: Healthy SubjectsView official trial listing → -
Not yet recruiting NCT NCT07239414
Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability
Not yet reported Sohaib Ashraf 690 participants Est. completion 2027-02-21Other conditions: CardiovascularView official trial listing → -
Completed NCT NCT07255820
Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
Not yet reported Bahria University 126 participants Est. completion 2026-06-30 1 siteType 2 diabetes Other conditions: Hypercholesterolemia / Elevated LDL CholesterolView official trial listing → -
Not yet recruiting NCT NCT07256171
COAST Study - Cholesterol Optimization After Stroke
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 500 participants Est. completion 2026-12-31Cardiovascular disease Other conditions: Cerebral HemorrhageView official trial listing → -
Completed NCT NCT07268625
Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin
Not yet reported Daiichi Sankyo 58 participants Est. completion 2026-02-24 1 site Stand-aloneOther conditions: Healthy SubjectsView official trial listing → -
Not yet recruiting NCT NCT07282821
Bempedoic Acid Therapy for Polycystic Kidney Disease
Not yet reported Kenneth Hallows 120 participants Est. completion 2030-03-31 3 sitesOther conditions: ADPKD (Autosomal Dominant Polycystic Kidney Disease)View official trial listing → -
Not yet recruiting NCT NCT07440381
triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE
Not yet reported Heart Care Foundation 600 participants Est. completion 2027-08 35 sites Stand-aloneOther conditions: Acute Coronary Syndromes, Secondary Prevention, LipidsView official trial listing → -
Not yet recruiting NCT NCT07474649
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Not yet reported Daiichi Sankyo 103 participants Est. completion 2028-10-02 12 sites Stand-aloneOther conditions: Coronary Atherosclerosis, Mixed Dyslipidemia, HypercholesterolemiaView official trial listing → -
Not yet recruiting NCT NCT07508254
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Not yet reported Punjab Institute of Cardology 120 participants Est. completion 2026-10-31 1 site Stand-aloneOther conditions: Acute Coronary Syndromes (ACS), HypercholesterolemiaView official trial listing → -
Not yet recruiting NCT NCT07623915
A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid
Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 222 participants Est. completion 2027-08-28 Stand-aloneOther conditions: Primary HyperlipidemiaView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Bempedoic Acid, Nexlizet, Nexletol
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.